menu

The Current and Future Role of Immuno-Oncologic Agents in Early-Stage, Locally Advanced, and Metastatic NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Current and Future Role of Immuno-Oncologic Agents in Early-Stage, Locally Advanced, and Metastatic NSCLC

3 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen in as Drs. Debora Bruno, Gilberto Lopes, and Solange Peters discuss the most recent data for immunotherapy in early-stage, locally advanced, and metastatic NSCLC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Debora Bruno, MD
    Assistant Professor of Medicine
    Medical Director, University Hospitals Dahms Clinical Research Unit
    UH Cleveland Medical Center, Case Comprehensive Cancer Center
    Case Western Reserve University School of Medicine
    Cleveland, OH

    Research: AstraZeneca
    Consulting Fees: Amgen, AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, Mirati Therapeutics, Novartis, Tempus

    Faculty:
    Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
    Associate Director for Global Oncology
    Interim Chief, Division of Medical Oncology
    Sylvester Comprehensive Cancer Center
    The University of Miami
    Miami, FL

    Stock and Other Ownership Interests: Lucence Diagnostics, Xilis
    Honoraria: AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Janssen, Merck
    Consulting or Advisory Role: AstraZeneca, Pfizer
    Research Funding: AstraZeneca, E.R. Squibb & Sons, LLC, Lucence, Xilis
    Other Relationship: Mirati Therapeutics

    Solange Peters, MD, PhD
    Professor and Chair, Medical Oncology
    Oncology Department, CHUV
    Lausanne University
    Lausanne, Switzerland

    Consultant and/or Advisor: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, BeiGene, Biocartis, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Co., Ltd., Debiopharm International SA, ecancer, Elsevier, F. Hoffmann-La Roche/Genentech, Fishawack Health Group, Foundation Medicine, Inc., Illumina, Inc., Incyte, IQVIA Inc., Janssen Global Services, LLC, Lilly, Merck Serono, Merck Sharp & Dohme Corp., Merrimack, Novartis, Pfizer, PharmaMar AG, Phosplatin Therapeutics, Regeneron Pharmaceuticals Inc., Sanofi, Seattle Genetics, and Takeda Pharmaceutical Company Limited

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe optimal evidence-based treatment selection and sequencing recommendations for the use of immuno-oncologic therapy in patients with early-stage NSCLC
    • Evaluate clinical trial data of emerging immunotherapy-based agents in the treatment of metastatic NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pulmonologists, pathologists, oncology nurses, pharmacists, and other oncology HCPs involved in the treatment of patients with lung cancer globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Panel Discussion activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until November 30, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .50 contact hours/0.05 CEUs of Pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-22-056-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Daiichi Sankyo, Inc.
    Genentech, a member of the Roche Group.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen in as Drs. Debora Bruno, Gilberto Lopes, and Solange Peters discuss the most recent data for immunotherapy in early-stage, locally advanced, and metastatic NSCLC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Debora Bruno, MD
    Assistant Professor of Medicine
    Medical Director, University Hospitals Dahms Clinical Research Unit
    UH Cleveland Medical Center, Case Comprehensive Cancer Center
    Case Western Reserve University School of Medicine
    Cleveland, OH

    Research: AstraZeneca
    Consulting Fees: Amgen, AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, Mirati Therapeutics, Novartis, Tempus

    Faculty:
    Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
    Associate Director for Global Oncology
    Interim Chief, Division of Medical Oncology
    Sylvester Comprehensive Cancer Center
    The University of Miami
    Miami, FL

    Stock and Other Ownership Interests: Lucence Diagnostics, Xilis
    Honoraria: AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Janssen, Merck
    Consulting or Advisory Role: AstraZeneca, Pfizer
    Research Funding: AstraZeneca, E.R. Squibb & Sons, LLC, Lucence, Xilis
    Other Relationship: Mirati Therapeutics

    Solange Peters, MD, PhD
    Professor and Chair, Medical Oncology
    Oncology Department, CHUV
    Lausanne University
    Lausanne, Switzerland

    Consultant and/or Advisor: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, BeiGene, Biocartis, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Co., Ltd., Debiopharm International SA, ecancer, Elsevier, F. Hoffmann-La Roche/Genentech, Fishawack Health Group, Foundation Medicine, Inc., Illumina, Inc., Incyte, IQVIA Inc., Janssen Global Services, LLC, Lilly, Merck Serono, Merck Sharp & Dohme Corp., Merrimack, Novartis, Pfizer, PharmaMar AG, Phosplatin Therapeutics, Regeneron Pharmaceuticals Inc., Sanofi, Seattle Genetics, and Takeda Pharmaceutical Company Limited

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe optimal evidence-based treatment selection and sequencing recommendations for the use of immuno-oncologic therapy in patients with early-stage NSCLC
    • Evaluate clinical trial data of emerging immunotherapy-based agents in the treatment of metastatic NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pulmonologists, pathologists, oncology nurses, pharmacists, and other oncology HCPs involved in the treatment of patients with lung cancer globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Panel Discussion activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until November 30, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .50 contact hours/0.05 CEUs of Pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-22-056-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Daiichi Sankyo, Inc.
    Genentech, a member of the Roche Group.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule8 Feb 2023